In a first-in-human phase I trial performed in the United States for patients with advanced HCC, GC33 was well-tolerated and antitumor effects were observed in some patients with high GPC3 expression HCC (Table 1) (36). The gene discussed is GPC3; the disease is hepatocellular carcinoma.